Search research articles
Contact Us
Filters
Showing results (11-20 of 73) with videos related to
Page
of 8
Sort By:
Cancer
|
March 11, 2011
Toward predictors of survival in castration-resistant prostate cancer
Julie N Graff, Tomasz M Beer
Cancer
|
July 3, 2013
The role of C-reactive protein in prostate cancer
Julie N Graff, Tomasz M Beer
Federal Practitioner : for the Health Care Professionals of the VA, Dod, and PHS
|
September 10, 2020
Leveraging Veterans Health Administration Clinical and Research Resources to Accelerate Discovery and Testing in Precision Oncology
Julie N Graff, Grant D Huang
Oncology (Williston Park, N.Y.)
|
April 18, 2016
Treatment of Nonmetastatic Castration-Resistant Prostate Cancer
Jia Luo, Tomasz M Beer, Julie N Graff
Oncology (Williston Park, N.Y.)
|
March 27, 2020
The Relationship Between Checkpoint Inhibitors and the Gut Microbiome and Its Application in Prostate Cancer
Ashray Maniar, Amy E Moran, Julie N Graff
Oncology (Williston Park, N.Y.)
|
January 12, 2019
Gonadotropin-Releasing Hormone Antagonists in Prostate Cancer
Adam S Kittai, Jessica Blank, Julie N Graff
JAMA Oncology
|
November 5, 2016
Should Chemotherapy Be Used in Nonmetastatic Prostate Cancer?
Julie N Graff, Joshi J Alumkal, Tomasz M Beer
Oncology (Williston Park, N.Y.)
|
August 28, 2013
Targeted therapy in prostate cancer: is there hope beyond the androgen receptor?
Joshi J Alumkal, Julie N Graff, Tomasz M Beer
Expert Opinion on Pharmacotherapy
|
February 18, 2015
Safety and effectiveness of enzalutamide in men with metastatic, castration-resistant prostate cancer
Julie N Graff, Max J Gordon, Tomasz M Beer
Urology
|
February 5, 2013
Complete biochemical (prostate-specific antigen) response to sipuleucel-T with enzalutamide in castration-resistant prostate cancer: a case report with implications for future research
Julie N Graff, Charles G Drake, Tomasz M Beer
Page
of 8
Search research articles
Search
Showing results (11-20 of 73) with videos related to
Sort By:
Page
of 8
Cancer
|
March 11, 2011
Toward predictors of survival in castration-resistant prostate cancer
Julie N Graff, Tomasz M Beer
Cancer
|
July 3, 2013
The role of C-reactive protein in prostate cancer
Julie N Graff, Tomasz M Beer
Federal Practitioner : for the Health Care Professionals of the VA, Dod, and PHS
|
September 10, 2020
Leveraging Veterans Health Administration Clinical and Research Resources to Accelerate Discovery and Testing in Precision Oncology
Julie N Graff, Grant D Huang
Oncology (Williston Park, N.Y.)
|
April 18, 2016
Treatment of Nonmetastatic Castration-Resistant Prostate Cancer
Jia Luo, Tomasz M Beer, Julie N Graff
Oncology (Williston Park, N.Y.)
|
March 27, 2020
The Relationship Between Checkpoint Inhibitors and the Gut Microbiome and Its Application in Prostate Cancer
Ashray Maniar, Amy E Moran, Julie N Graff
Oncology (Williston Park, N.Y.)
|
January 12, 2019
Gonadotropin-Releasing Hormone Antagonists in Prostate Cancer
Adam S Kittai, Jessica Blank, Julie N Graff
JAMA Oncology
|
November 5, 2016
Should Chemotherapy Be Used in Nonmetastatic Prostate Cancer?
Julie N Graff, Joshi J Alumkal, Tomasz M Beer
Oncology (Williston Park, N.Y.)
|
August 28, 2013
Targeted therapy in prostate cancer: is there hope beyond the androgen receptor?
Joshi J Alumkal, Julie N Graff, Tomasz M Beer
Expert Opinion on Pharmacotherapy
|
February 18, 2015
Safety and effectiveness of enzalutamide in men with metastatic, castration-resistant prostate cancer
Julie N Graff, Max J Gordon, Tomasz M Beer
Urology
|
February 5, 2013
Complete biochemical (prostate-specific antigen) response to sipuleucel-T with enzalutamide in castration-resistant prostate cancer: a case report with implications for future research
Julie N Graff, Charles G Drake, Tomasz M Beer
Page
of 8